158 related articles for article (PubMed ID: 36621256)
1. A radioiodinated rucaparib analogue as an Auger electron emitter for cancer therapy.
Destro G; Chen Z; Chan CY; Fraser C; Dias G; Mosley M; Guibbal F; Gouverneur V; Cornelissen B
Nucl Med Biol; 2023; 116-117():108312. PubMed ID: 36621256
[TBL] [Abstract][Full Text] [Related]
2. [
Chan CY; Chen Z; Guibbal F; Dias G; Destro G; O'Neill E; Veal M; Lau D; Mosley M; Wilson TC; Gouverneur V; Cornelissen B
J Nucl Med; 2023 Dec; 64(12):1965-1971. PubMed ID: 37770109
[TBL] [Abstract][Full Text] [Related]
3. Imaging PARP with [
Chan CY; Chen Z; Destro G; Veal M; Lau D; O'Neill E; Dias G; Mosley M; Kersemans V; Guibbal F; Gouverneur V; Cornelissen B
Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3668-3678. PubMed ID: 35614267
[TBL] [Abstract][Full Text] [Related]
4. Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer.
García-Parra J; Dalmases A; Morancho B; Arpí O; Menendez S; Sabbaghi M; Zazo S; Chamizo C; Madoz J; Eroles P; Servitja S; Tusquets I; Yelamos J; Lluch A; Arribas J; Rojo F; Rovira A; Albanell J
Eur J Cancer; 2014 Oct; 50(15):2725-34. PubMed ID: 25128455
[TBL] [Abstract][Full Text] [Related]
5. Preclinical studies of a PARP targeted, Meitner-Auger emitting, theranostic radiopharmaceutical for metastatic ovarian cancer.
Hoffman SLV; Mixdorf JC; Kwon O; Johnson TR; Makvandi M; Lee H; Aluicio-Sarduy E; Barnhart TE; Jeffery JJ; Patankar MS; Engle JW; Bednarz BP; Ellison PA
Nucl Med Biol; 2023; 122-123():108368. PubMed ID: 37490805
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy.
Jenner ZB; Sood AK; Coleman RL
Future Oncol; 2016 Jun; 12(12):1439-56. PubMed ID: 27087632
[TBL] [Abstract][Full Text] [Related]
7. Niraparib Shows Superior Tissue Distribution and Efficacy in a Prostate Cancer Bone Metastasis Model Compared with Other PARP Inhibitors.
Snyder LA; Damle R; Patel S; Bohrer J; Fiorella A; Driscoll J; Hawkins R; Stratton CF; Manning CD; Tatikola K; Tryputsen V; Packman K; Mamidi RNVS
Mol Cancer Ther; 2022 Jul; 21(7):1115-1124. PubMed ID: 35499386
[TBL] [Abstract][Full Text] [Related]
8. Current status and progress in using radiolabelled PARP-1 inhibitors for imaging PARP-1 expression in tumours.
Wang Q; Zhang J
Eur J Med Chem; 2022 Nov; 242():114690. PubMed ID: 36041258
[TBL] [Abstract][Full Text] [Related]
9. [
Guibbal F; Hopkins SL; Pacelli A; Isenegger PG; Mosley M; Torres JB; Dias GM; Mahaut D; Hueting R; Gouverneur V; Cornelissen B
Mol Imaging Biol; 2020 Oct; 22(5):1226-1234. PubMed ID: 32342268
[TBL] [Abstract][Full Text] [Related]
10. Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules.
Murray J; Thomas H; Berry P; Kyle S; Patterson M; Jones C; Los G; Hostomsky Z; Plummer ER; Boddy AV; Curtin NJ
Br J Cancer; 2014 Apr; 110(8):1977-84. PubMed ID: 24556618
[TBL] [Abstract][Full Text] [Related]
11. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib.
Murai J; Huang SY; Renaud A; Zhang Y; Ji J; Takeda S; Morris J; Teicher B; Doroshow JH; Pommier Y
Mol Cancer Ther; 2014 Feb; 13(2):433-43. PubMed ID: 24356813
[TBL] [Abstract][Full Text] [Related]
12. An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma.
Nile DL; Rae C; Hyndman IJ; Gaze MN; Mairs RJ
BMC Cancer; 2016 Aug; 16():621. PubMed ID: 27515310
[TBL] [Abstract][Full Text] [Related]
13. Poly(ADP-ribose) polymerase inhibitors in prostate cancer: a cornerstone in precision oncology.
Ziadeh T; Kourie HR
Pharmacogenomics; 2021 Dec; 22(18):1237-1250. PubMed ID: 34729995
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and Evaluation of a Radioiodinated Tracer with Specificity for Poly(ADP-ribose) Polymerase-1 (PARP-1) in Vivo.
Zmuda F; Malviya G; Blair A; Boyd M; Chalmers AJ; Sutherland A; Pimlott SL
J Med Chem; 2015 Nov; 58(21):8683-93. PubMed ID: 26469301
[TBL] [Abstract][Full Text] [Related]
15. Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer.
Cardnell RJ; Feng Y; Mukherjee S; Diao L; Tong P; Stewart CA; Masrorpour F; Fan Y; Nilsson M; Shen Y; Heymach JV; Wang J; Byers LA
PLoS One; 2016; 11(4):e0152584. PubMed ID: 27055253
[TBL] [Abstract][Full Text] [Related]
16. PARP-1-Targeted Auger Emitters Display High-LET Cytotoxic Properties In Vitro but Show Limited Therapeutic Utility in Solid Tumor Models of Human Neuroblastoma.
Lee H; Riad A; Martorano P; Mansfield A; Samanta M; Batra V; Mach RH; Maris JM; Pryma DA; Makvandi M
J Nucl Med; 2020 Jun; 61(6):850-856. PubMed ID: 31676730
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
18. PET Imaging of PARP Expression Using
Wilson TC; Xavier MA; Knight J; Verhoog S; Torres JB; Mosley M; Hopkins SL; Wallington S; Allen PD; Kersemans V; Hueting R; Smart S; Gouverneur V; Cornelissen B
J Nucl Med; 2019 Apr; 60(4):504-510. PubMed ID: 30389822
[TBL] [Abstract][Full Text] [Related]
19. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
Antonarakis ES; Gomella LG; Petrylak DP
Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685
[TBL] [Abstract][Full Text] [Related]
20. PARP and PARG inhibitors in cancer treatment.
Slade D
Genes Dev; 2020 Mar; 34(5-6):360-394. PubMed ID: 32029455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
